scholarly journals Faculty Opinions recommendation of In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae.

2020 ◽  
Author(s):  
Catriona Bradshaw
Keyword(s):  
Neisseria Gonorrhoeae ◽  
Vitro Activity ◽  
The Novel ◽  
In Vitro Activity

scholarly journals In vitro activity of 14 antimicrobial agents against Neisseria gonorrhoeae from Spain.

1987 ◽  
Vol 63 (3) ◽  
pp. 215-216
Author(s):  
M C Lozano ◽  
J C Palomares ◽  
R Prados ◽  
E J Perea
Keyword(s):  
Neisseria Gonorrhoeae ◽  
Antimicrobial Agents ◽  
Vitro Activity ◽  
In Vitro Activity

scholarly journals In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis

2017 ◽  
Vol 72 (5) ◽  
pp. 1355-1358 ◽  
Author(s):  
Dina A. Boikov ◽  
Jeffrey B. Locke ◽  
Kenneth D. James ◽  
Ken Bartizal ◽  
Jack D. Sobel
Keyword(s):  
Vulvovaginal Candidiasis ◽  
Vitro Activity ◽  
The Novel ◽  
In Vitro Activity ◽  
Candida Spp

scholarly journals In vitro activity of a new fluoroquinolone, CP-99,219, against strains of Neisseria gonorrhoeae.

1995 ◽  
Vol 39 (4) ◽  
pp. 987-989 ◽  
Author(s):  
J S Knapp ◽  
S W Neal ◽  
M C Parekh ◽  
R J Rice
Keyword(s):  
Neisseria Gonorrhoeae ◽  
Vitro Activity ◽  
In Vitro Activity

The susceptibilities of 216 strains of Neisseria gonorrhoeae to a new fluoroquinolone, CP-99,219 were determined. For strains for which the MICs of ciprofloxacin were < or = 0.06 microgram/ml, the MICs at which 90% of the isolates are inhibited (MIC90s) of CP-99,219, ciprofloxacin, and ofloxacin were 0.008, 0.015, and 0.03 microgram/ml, respectively. For strains for which the MICs of ciprofloxacin were 0.125 to 0.5 microgram/ml, the MIC90s of CP-99,219, ciprofloxacin, and ofloxacin were 0.06, 0.25, and 0.5 microgram/ml, respectively. For strains for which the MICs of ciprofloxacin and ofloxacin were 2.0 micrograms/ml, the MIC of CP-99,219 was 0.25 microgram/ml.

In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile

2020 ◽  
Author(s):  
Beverly Murray ◽  
Cindy Wolfe ◽  
Andrea Marra ◽  
Chris Pillar ◽  
Dean Shinabarger
Keyword(s):  
Therapeutic Potential ◽  
Oral Treatment ◽  
Clinical Development ◽  
Vitro Activity ◽  
The Novel ◽  
In Vitro Activity ◽  
Clostridioides Difficile ◽  
Clostridioides Difficile Infection ◽  
Time Kill

Abstract Background Ibezapolstat (ACX-362E) is the first DNA polymerase IIIC inhibitor undergoing clinical development for the oral treatment of Clostridioides difficile infection (CDI). Methods In this study, the in vitro activity of ibezapolstat was evaluated against a panel of 104 isolates of C. difficile, including those with characterized ribotypes (e.g. 027 and 078) and those producing toxin A or B and was shown to have similar activity to those of comparators against these strains. Results The overall MIC50/90 (mg/L) for ibezapolstat against evaluated C. difficile was 2/4, compared with 0.5/4 for metronidazole, 1/4 for vancomycin and 0.5/2 for fidaxomicin. In addition, the bactericidal activity of ibezapolstat was evaluated against actively growing C. difficile by determining the MBC against three C. difficile isolates. Time–kill kinetic assays were additionally performed against the three C. difficile isolates, with metronidazole and vancomycin as comparators. Conclusions The killing of C. difficile by ibezapolstat was observed to occur at concentrations similar to its MIC, as demonstrated by MBC:MIC ratios and reflected in time–kill kinetic assays. This activity highlights the therapeutic potential of ibezapolstat for the treatment of CDI.

Sign in / Sign up

Export Citation Format

Share Document